Abstract
Sympathetic nerve activity (SNA) is increased in both patients and experimental animals with renal failure. The kidney is a richly innervated organ and has both efferent and afferent nerves. Renal denervation shows protective effects against renal failure in both animals and humans. The underlying mechanisms include a decrease in blood pressure, a decrease in renal efferent SNA, a decrease in central SNA and sympathetic outflow, and downregulation of the reninangiotensin system. It has been demonstrated that re-innervation occurs within weeks after renal denervation in animals but that no functional re-innervation occurs in humans for over two years after denervation. Renal denervation might not be renal protective in some situations including bile duct ligation-induced renal failure and ischemia/reperfusion-induced acute kidney injury. Catheter-based renal denervation has been applied to patients with both early and end stage renal failure and the published results so far suggest that this procedure is safe and effective at decreasing blood pressure. The effectiveness of renal denervation in improving renal function in patients with renal failure needs to be further investigated.
Keywords: Acute kidney injury, chronic kidney disease, re-innervation, renal denervation, sympathetic nerve activity
Current Neurovascular Research
Title:Therapeutic Effects of Renal Denervation on Renal Failure
Volume: 10 Issue: 2
Author(s): Yutang Wang, Sai-Wang Seto and Jonathan Golledge
Affiliation:
Keywords: Acute kidney injury, chronic kidney disease, re-innervation, renal denervation, sympathetic nerve activity
Abstract: Sympathetic nerve activity (SNA) is increased in both patients and experimental animals with renal failure. The kidney is a richly innervated organ and has both efferent and afferent nerves. Renal denervation shows protective effects against renal failure in both animals and humans. The underlying mechanisms include a decrease in blood pressure, a decrease in renal efferent SNA, a decrease in central SNA and sympathetic outflow, and downregulation of the reninangiotensin system. It has been demonstrated that re-innervation occurs within weeks after renal denervation in animals but that no functional re-innervation occurs in humans for over two years after denervation. Renal denervation might not be renal protective in some situations including bile duct ligation-induced renal failure and ischemia/reperfusion-induced acute kidney injury. Catheter-based renal denervation has been applied to patients with both early and end stage renal failure and the published results so far suggest that this procedure is safe and effective at decreasing blood pressure. The effectiveness of renal denervation in improving renal function in patients with renal failure needs to be further investigated.
Export Options
About this article
Cite this article as:
Wang Yutang, Seto Sai-Wang and Golledge Jonathan, Therapeutic Effects of Renal Denervation on Renal Failure, Current Neurovascular Research 2013; 10 (2) . https://dx.doi.org/10.2174/1567202611310020010
DOI https://dx.doi.org/10.2174/1567202611310020010 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Attenuation of Diabetes-induced Cardiac and Subcellular Defects by Sulphur-containing Amino Acids
Current Medicinal Chemistry Epicardial and Intramyocardial Adipose Tissue: The Enemy within
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prognostic Utility of Troponin I and N Terminal-ProBNP among Patients with Heart Failure due to Non-Ischemic Cardiomyopathy and Important Correlations
Cardiovascular & Hematological Agents in Medicinal Chemistry Oxidative Stress and Lipid Peroxidation in Prolonged Users of Methamphetamine
Drug Metabolism Letters Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Risk Prediction Models and Scores in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Sudden Infant Death Syndrome from Epidemiology to Pathophysiology
Current Pediatric Reviews Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews The Evolving Roles of Nuclear Cardiology
Current Cardiology Reviews Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Current Medicinal Chemistry Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts
Current Respiratory Medicine Reviews 10 Years of SELDI: What Have we Learnt?
Current Proteomics Nearly 200 X-Ray Crystal Structures of Transthyretin: What Do They Tell Us About This Protein and the Design of Drugs for TTR Amyloidoses?
Current Medicinal Chemistry Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry The Role of Flavonoids in Inhibiting IL-6 and Inflammatory Arthritis
Current Topics in Medicinal Chemistry Drug Uptake Systems in Liver and Kidney
Current Drug Metabolism Targeting the Fatty Acid Transport Proteins (FATP) to Understand the Mechanisms Linking Fatty Acid Transport to Metabolism
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)